Massey is currently offering clinical trials for patients with early-stage lung cancer that utilize cutting-edge precision medicine techniques with the aim of improving treatment. This group of three integrated national clinical trials known as ALCHEMIST - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials - use next-generation sequencing to identify patients with early-stage lung cancer whose tumors harbor specific and uncommon changes in EGFR and ALK. The goal of ALCHEMIST is to determine whether treatments targeted against those particular gene alterations are more effective in preventing recurrence and improving survival than the current standard of care involving chemotherapy with or without radiotherapy after the tumor's removal. At Massey, the trial is led by Sherman Baker.